{"publication_id":"7ab156d6-8b98-4d64-9135-9b29624ec48e","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies","doi":"10.1016/j.phrs.2021.105836","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2","doi":"10.2215/cjn.10140620","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}